Senya Therapeutics

LRG1 therapeutic platform for chronic diseases.

Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform. This protein was identified as playing a key role in forming new vascular tissue in the retina, by Senya’s founders Professors Greenwood and Moss at the UCL Institute of Ophthalmology. 

It has since been shown to be involved in the progression of a range of human health conditions, including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. 

Senya Therapeutics holds the global patent rights for LRG1 as a therapeutic target, and is exploring how this can offer new ways to treat chronic diseases focusing on unment needs in nephrology and oncology.

The Senya journey so far:

  • 2019: The spinout company is initially founded as 'LRG1'
  • 2023: Senya Therapeutics is launched 
  • 2024: 
    • Senya Wins £0.7M Innovate UK Grant and £1.8M Seed Extension Round
    • Senya and University of Edinburgh Partner on Nephrology Research, and with Netherlands Cancer Institute (NKI) Collaborate on Cancer Research
  • 2026: Senya Therapeutics launches a Series A funding round to progress its lead compound through Phase 1 and 2 trials for treatment of chronic kidney disease.

Team

Professor John Greenwood

Co-founder and Chief Scientific Officer

Professor Greenwood is a vascular biologist with a strong research background in biomedical and translational research. He spent eight years as UCL Head of the Department of Cell Biology

Taskashi Takenoshita

CEO

Takashi is a seasoned biotech CEO with 30+ years' experience in the pharmaceutical industry. He was previously a Venture Partner at Oxford Science Enterprises and co-founder of Dark Blue Therapeutics.

Professor Emeritus Steve Moss, Co-found and Co-Chief Scientific Officer

Dr. Mark Fisher

Associate Director

Global Business School for Health

Dr Fisher is responsible for the BioPharm patent portfolio and strategic business support. He brings more than 30 years' experience in life sciences and healthcare licensing and company development.